ARTICLE | Clinical News
AnorMed ends AMD3100 program in HIV
May 25, 2001 7:00 AM UTC
AnorMed (TSE:AOM) said it will not proceed with the development of AMD3100 synthetic CXCR4 chemokine receptor antagonist to treat HIV infection, after two patients in a dose-escalating U.S. Phase Ia/I...